Clinical trial
Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection
NCT00127777 is registered in ClinicalTrials.gov with University Hospital, Saarland as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection
- Lead sponsor
- University Hospital, Saarland
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- July 31, 2002
- Completion date
- December 31, 2006
- Enrollment
- 700
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.